Absorption and disposition kinetics of lithium carbonate following administration of conventional and controlled release formulations
- PMID: 3089949
Absorption and disposition kinetics of lithium carbonate following administration of conventional and controlled release formulations
Abstract
The absorption and disposition kinetics of lithium carbonate administered to eight healthy volunteers in two dosage forms were studied. A conventional immediate release tablet and a controlled release preparation, developed in our laboratory and containing the drug into a hydrophilic matrix, were employed in the study. Lithium carbonate confers upon the body the distinct characteristics of a two-compartment open model with a mean slow disposition rate constant (beta) of 0.0435 h-1 +/- 0.0086 SD, corresponding to a mean biological half-life of 16.49 h +/- 2.95 SD. The mean half-life of the distributory alpha-phase was 1.40 h +/- 0.27 SD. The apparent volume of distribution (Vdarea) was 0.539 l kg-1 +/- 0.130 SD and the volume of the central compartment (Vl) was 0.224 l/kg-1 +/- 0.066 SD, about one half that of the volume at steady state (Vdss) which was 0.445 l/kg-1 +/- 0.106 SD. Total body clearance (ClB) was 0.0241 l/kg-1 h +/- 0.0102 SD. The administration of the controlled release preparations to the same subjects gave the expected smooth serum lithium concentration curves. Maximum serum concentration (Cmax) was 22% lower and the time at which this concentration was attained (tpeak) was delayed from 1.44 h to 4.25 h when compared with the conventional tablet. Bioavailability, estimated as the total amount of lithium excreted in the urine, was 90.2 for the controlled release preparation and 94.5 for the immediate release tablet.
Similar articles
-
Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring.CNS Drugs. 2009;23(4):331-49. doi: 10.2165/00023210-200923040-00005. CNS Drugs. 2009. PMID: 19374461 Review.
-
The bioavailability and kinetics of dihydroquinidine in patients with heart disease.Int J Clin Pharmacol Ther Toxicol. 1982 May;20(5):212-8. Int J Clin Pharmacol Ther Toxicol. 1982. PMID: 7095920
-
Bioavailability of lithium carbonate and lithium citrate: a comparison of two controlled-release preparations.Pharmatherapeutica. 1982;3(4):243-6. Pharmatherapeutica. 1982. PMID: 6815664 Clinical Trial.
-
Single-dose bioavailability of two extended-release lithium carbonate products.Am J Hosp Pharm. 1994 Feb 15;51(4):486-9. Am J Hosp Pharm. 1994. PMID: 8017413 Clinical Trial.
-
Serum level monitoring and clinical pharmacokinetics of lithium.Clin Pharmacokinet. 1977 Mar-Apr;2(2):73-92. doi: 10.2165/00003088-197702020-00001. Clin Pharmacokinet. 1977. PMID: 324690 Review.
Cited by
-
Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring.CNS Drugs. 2009;23(4):331-49. doi: 10.2165/00023210-200923040-00005. CNS Drugs. 2009. PMID: 19374461 Review.
-
Using Lithium in Children and Adolescents with Bipolar Disorder: Efficacy, Tolerability, and Practical Considerations.Paediatr Drugs. 2018 Aug;20(4):303-314. doi: 10.1007/s40272-018-0289-x. Paediatr Drugs. 2018. PMID: 29651656 Review.
-
An overview of boron, lithium, and strontium in human health and profiles of these elements in urine of Japanese.Environ Health Prev Med. 2007 Nov;12(6):231-7. doi: 10.1007/BF02898029. Environ Health Prev Med. 2007. PMID: 21432068 Free PMC article.
-
Designing and characterizing first Iranian study evaluating serum levels of lithium in patients for population pharmacokinetics (FIRELOLIPOP): baseline and first report.Sci Rep. 2025 May 3;15(1):15514. doi: 10.1038/s41598-025-99698-y. Sci Rep. 2025. PMID: 40319121 Free PMC article.
-
Formulation and in vitro-in vivo evaluation of sustained-release lithium carbonate tablets.Pharm Res. 1990 Apr;7(4):359-63. doi: 10.1023/a:1015863204732. Pharm Res. 1990. PMID: 2114020
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources